Apex Healthcare

What Apex Healthcare does

Apex Healthcare Berhad is a Singapore-headquartered, Malaysia-operating pharmaceutical group founded in 1962 in Melaka as a retail pharmacy and now operating across three integrated business segments: Manufacturing (Xepa-Soul Pattinson develops, manufactures, and markets XEPA-branded off-patent generic pharmaceuticals and medical devices from a 39,484 sqm EU GMP, PIC/S, ISO 9001:2015, ISO/IEC 17025, EN ISO 13485, GDPMD, and Halal-certified facility in Melaka, with more than 250 core products supporting over 700 product registrations across 17 territories); Distribution (Apex Pharma Malaysia is described as Malaysia's leading pharmaceutical and consumer healthcare wholesaler, supplemented by Apex Pharma Singapore and a 2017-launched Apex Pharmacy e-commerce platform, collectively operating 8 distribution facilities with SAP-linked inventory serving 16,000+ customer accounts and processing 600,000+ invoices annually); and Corporate (Straits Apex Group for orthopaedic device contract manufacturing under a 16% effective equity stake, and the Zynexis joint venture with Shanghai Pharmaceuticals Holding for ASEAN and international commercialization).

The Group makes money through three primary revenue streams: branded generics and medical device sales plus contract manufacturing (one-time license/transaction revenue), distribution and wholesaling services for international principals (transaction-fee economics), and international commercialization through the Zynexis joint venture (licensing/royalty-style revenue). Group branded products contribute more than 30% of revenue. The customer base is hybrid and diversified, serving healthcare professionals and institutions (clinics, polyclinics, pharmacies, hospitals in Malaysia and the region), end consumers (via Apex Pharmacy retail and e-commerce), pharmaceutical principals requiring specialist market access, and global medical device companies through Straits Apex Group. Apex Healthcare Berhad was taken private in January 2026 by a Quadria Capital-led consortium (with 65 Equity Partners, Silk Road Fund, and Malaysia's Employees Provident Fund) in a USD 470 million (MYR 1.9 billion) transaction, the largest healthcare buyout in Southeast Asia in the past five years.

Name

Apex Healthcare

Legal name

Apex Healthcare Berhad 199801016979 (473108-T)

Website

https://apexhealthcare.com.my

Company type

Private

Founded year

1962

Operating status

Acquired

Headcount range

501–1,000 employees

Short description

Apex Healthcare is a Singapore-headquartered pharmaceutical group operating in Malaysia that manufactures XEPA-branded generic pharmaceuticals and medical devices, distributes pharmaceuticals and consumer healthcare products through 8 facilities in Malaysia and Singapore serving 16,000+ customers, and contract-manufactures orthopaedic devices via Straits Apex Group.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing and Distribution

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmacies and Drug Retailers (45611), Ophthalmic Goods Merchant Wholesalers (423460)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Generic pharmaceutical manufacturing
• Pharmaceutical distribution services
• Contract manufacturing orthopaedics
• Medical device manufacturing
• Consumer healthcare products

Headquarters

HQ city

Melaka

HQ country

Malaysia

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical and Medical Device Manufacturing: Revenue from development, manufacturing, sales and marketing of XEPA branded off-patent generic pharmaceuticals and medical devices. Also includes contract manufacturing services for major pharmaceutical companies. Group branded products contribute more than 30% to the Group's revenue.
2. Distribution and Wholesaling: Revenue from specialist market access services including regulatory, redressing, sales, marketing and logistics services via network of 8 distribution facilities. Also distributes internationally known brands such as Nestle, 3M and Rigel Pharma. Apex Pharma Malaysia is Malaysia's leading pharmaceutical and consumer healthcare wholesaler. Processes over 2,000 invoices per working day, totaling more than 600,000 invoices annually.
3. Orthopaedic Contract Manufacturing: Revenue from contract manufacturing of surgical grade orthopaedic devices, components and surgical instruments for global multinational companies through Straits Apex Group (40% owned associate). Products include screws, plates, implants, intra-medullary nails, pins, external fixators used in surgical treatment of musculoskeletal disorders.
4. International Commercialization: Revenue from commercialization of pharmaceuticals, consumer healthcare products and medical devices under Zynexis brand in selected ASEAN countries and other international markets through joint venture with Shanghai Pharmaceuticals Holding Co. Ltd.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels4 records

Core offering

Apex Healthcare develops, manufactures and markets XEPA-branded off-patent generic pharmaceuticals and medical devices through its Xepa-Soul Pattinson subsidiary, supported by EU GMP, PIC/S and ISO-certified facilities in Melaka. The company also operates Apex Pharma Malaysia and Apex Pharma Singapore as pharmaceutical and consumer healthcare wholesalers/distributors across 8 distribution facilities, runs the Apex Pharmacy retail and e-commerce pharmacy business, contract manufactures orthopaedic devices through Straits Apex Group, and commercializes products under the Zynexis brand in ASEAN via its joint venture with Shanghai Pharmaceuticals.

Product overview

Apex Healthcare is a pharmaceutical group operating through three main business segments: Manufacturing (Xepa-Soul Pattinson brand), Distribution (Apex Pharma Malaysia, Apex Pharma Singapore, and Apex Pharmacy retail/e-commerce), and Corporate (Straits Apex Group for orthopaedics contract manufacturing and Zynexis for ASEAN/international commercialization). The company holds over 700 Group branded product registrations across 17 territories with a core portfolio of more than 250 products, contributing more than 30% to Group revenue. Products span off-patent generic pharmaceuticals, medical devices, and consumer healthcare products, supported by 8 distribution facilities in Singapore and Malaysia serving over 16,000 customer accounts.

Differentiator

Problem solved

Functional benefit

Brands

• XEPA: XEPA branded off-patent generic pharmaceuticals and medical devices marketed by Xepa-Soul Pattinson.
• Xepa-Soul Pattinson
• Apex Pharma Centre
• Apex Pharmacy
• Apex Pharma Marketing
• Abio Marketing
• Straits Apex Group
• Zynexis

Products and services

• XEPA Branded Generic Pharmaceuticals and Medical Devices Development, manufacture and marketing of XEPA branded off-patent generic pharmaceuticals and medical devices including cough mixtures, antihistamines, anti-infectives, anti-diabetics, anti-hypertensives, neuromuscular agents, analgesics, dermatologicals and ophthalmologicals (tablets, capsules, oral liquids, suspensions, creams, sterile eye drops), sold to healthcare professionals and institutions across Malaysia and the region. Also includes contract manufacturing for major pharmaceutical companies.
• Apex Pharma Malaysia Distribution and Wholesaling Specialist market access services for pharmaceutical companies, providing regulatory, sales, marketing, redressing and logistics services across Malaysia. Distributes internationally known brands such as Nestle, 3M and Rigel Pharma to clinics, polyclinics, pharmacies and hospitals nationwide. Processes over 2,000 invoices per working day and over 600,000 invoices annually.
• Apex Pharma Singapore Distribution Wholesaling, marketing and distribution services for pharmaceutical products in Singapore, operating from a 50,000 sq ft purpose-designed industrial facility with additional warehouse space recently leased to expand storage and distribution capacity.
• Apex Pharmacy Retail and E-commerce Retail pharmacy with both physical storefronts and an online e-commerce platform selling consumer healthcare products, medicated powders and over-the-counter wellness products directly to Malaysian consumers.
• Straits Apex Group Orthopaedic Contract Manufacturing Contract manufacturing of surgical grade orthopaedic devices, components and surgical instruments including screws, plates, implants, intra-medullary nails, pins and external fixators used in treatment of musculoskeletal disorders, supplied to global multinational medical device companies.
• Zynexis ASEAN and International Commercialization ASEAN and international commercialization of pharmaceuticals, consumer healthcare products and medical devices under the Zynexis brand, combining SPH's new-generation generics and innovative pharmaceuticals with Apex Healthcare's regional footprint across selected ASEAN countries and other international markets.

Quantifiable outcome

• 700+ Group branded product registrations across 17 territories
• +6 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Shanghai Pharmaceuticals Holding Co. Ltd. (SPH)coreStrategic or Co-development Partner · 1 January 2022Fortune Global 500 company based in Shanghai, China with dual listings on Shanghai and Hong Kong stock exchanges. Entered into subscription and shareholder agreement with Apex Healthcare's wholly-owned Singapore subsidiary First SGC Pte Ltd to subscribe SGD 1.2 million (RM 3.9 million) for 40% equity in Zynexis Healthcare Private Ltd. Joint venture serves as vehicle to commercialize pharmaceuticals, consumer healthcare products and medical devices from SPH and Apex Healthcare Group under Zynexis brand in selected ASEAN countries and other international markets. Extends Apex's capabilities to offer new generation generics as well as leading edge novel and innovative pharmaceutical products to ASEAN markets.
• NestleminorChannel Partner/ Reseller/ DistributorInternational brand distributed by Apex Pharma Malaysia as part of its distribution portfolio of internationally known brands.
• 3MminorChannel Partner/ Reseller/ DistributorInternational brand distributed by Apex Pharma Malaysia as part of its distribution portfolio of internationally known brands.
• Rigel PharmaminorChannel Partner/ Reseller/ DistributorInternational brand distributed by Apex Pharma Malaysia as part of its distribution portfolio of internationally known brands.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Hovid Berhad: Malaysian generic pharmaceutical manufacturer with exports to over 30 countries and an established OTC and prescription generics portfolio. Closely comparable to Xepa-Soul Pattinson in product mix, scale and Malaysian/regional customer base.
• Kotra Pharma Berhad: Malaysian-listed generic pharmaceutical manufacturer focused on prescription and OTC generics, vitamins and traditional medicines. Direct comparator on Malaysian generic manufacturing footprint and ASEAN export orientation.
• Pharmaniaga Berhad: Malaysia's largest pharmaceutical manufacturer and distributor by volume with government-linked concession for Ministry of Health medicine supply. Competes head-to-head with Apex Healthcare across both generic manufacturing (vs. Xepa) and pharmaceutical distribution (vs. Apex Pharma Malaysia).
• YSP Industries Berhad: Malaysian pharmaceutical manufacturer specializing in generic and branded generics, sterile and non-sterile dosage forms, with PIC/S GMP certification. Comparable to Xepa across regulatory certifications, product types and ASEAN export markets.
• Duopharma Biotech Berhad: Malaysian-listed manufacturer of generic pharmaceuticals and consumer healthcare products. Direct competitor to Xepa-Soul Pattinson in Malaysia's off-patent generic segment with comparable PIC/S GMP-certified manufacturing and government hospital tender exposure.

Broad incumbents

• DKSH Holding AG: Swiss-listed market expansion services group with a large Healthcare distribution business across ASEAN including Malaysia and Singapore. Comparable to Apex Pharma Malaysia/Singapore as a regional pharma distribution platform serving international brand principals.
• Zuellig Pharma Holdings: One of the largest pharmaceutical distributors in Asia, with significant ASEAN presence including Malaysia and Singapore. Comparable as a regional wholesaler and distribution services competitor to Apex Pharma's specialist market access business.

Emerging players

• Kalbe Farma: Indonesia's largest pharmaceutical company with broad generic, branded and consumer health portfolios across ASEAN. Relevant comparable for Apex Healthcare's regional expansion ambitions via Zynexis and Malaysia/Singapore distribution platform.
• Straits Orthopaedics: Malaysian orthopaedic device contract manufacturer and a member of the Straits Apex Group ecosystem. Closely comparable to Apex's Straits Apex Group segment that contract manufactures surgical-grade orthopaedic devices for global multinationals.

Others

• Shanghai Pharmaceuticals Holding: Fortune Global 500 Chinese pharmaceutical group and Apex Healthcare's JV partner in Zynexis Healthcare. Relevant peer/partner given the strategic relationship, comparable scope as a manufacturer of generics and innovative drugs serving ASEAN markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apex Healthcare